Skip to main content

Table 4 Acute toxicity of the IGEFA administered orally to different groups of mice

From: Anticonvulsant effects of iridoid glycosides fraction purified from Feretia apodanthera Del. (Rubiaceae) in experimental mice models of generalized tonic-clonic seizures

Treatment Dose (mg/kg) Sex D/T Mortality latency (h) Toxic symptoms
Vehicle Male 0/5 None
Female 0/5 None
IGEFA 5 Male 0/5 None
Female 0/5 None
IGEFA 15 Male 0/5 None
Female 0/5 None
IGEFA 30 Male 0/5 None
Female 0/5 None
IGEFA 90 Male 0/5 None
Female 0/5 None
IGEFA 180 Male 0/5 None
Female 0/5 None
IGEFA 360 Male 0/5 None
Female 0/5 None
IGEFA 720 Male 3/5 36–48 Hypoactivity, piloerection, salivation
Female 5/5 36–48 Hypoactivity, piloerection, salivation
IGEFA 1440 Male 4/5 24–36 Hypoactivity, piloerection, salivation
Female 5/5 24–36 Hypoactivity, piloerection, salivation
IGEFA 2880 Male 5/5 24–36 Hypoactivity, piloerection, salivation
Female 5/5 36–48 Hypoactivity, piloerection, salivation
IGEFA 5760 Male 5/5 36–48 Asthenia, anorexia, salivation, asthenia
Female 5/5 36–48 Asthenia, anorexia, salivation, asthenia
  1. D/T = Dead/Treated mice; None = No toxic symptoms during the observation period; mortality latency = time to death after the oral administration. The IGEFA was two groups of mice. Mice in each group were carefully examined for any signs of toxic (behavioural changes and mortality) for 14 days. Control group received vehicle (10 ml/kg, per os)